Aurobindo Pharma
Aurobindo Pharma
Shareholder Return: 3-year average, Sales Growth: 3-year Compounded Annual Growth Rate, Return On Equity: 3-year Return on Equity.
At a Glance
-
Shareholder Return897%
-
Sales Growth33%
-
Return on Equity35 %
Why Super 50
Founded in 1986, Aurobindo Pharma is among the top 10 drug manufacturers in India by revenue. Around 70 percent of its turnover comes from global markets, including the US and Europe. The drug maker is a market leader in semi-synthetic penicillin, apart from being present in therapeutic areas, including neurosciences and cardiovascular ailments. Faster approvals and market share gain in the US, and a turnaround of its European acquisition are expected to help the company's growth in the future.
